Biohaven Pharmaceutical Hold
13F holders, Q3 2024 (September 30)3holders
1new positions
1sold out
$49.97avg. 13F price*
At the end of Q3 2024, 3 institutions reported holding Biohaven Pharmaceutical Hold in their 13F filings, unchanged from Q2 2024. 1 opened new positions and 1 sold out. The largest holders were Knoll Capital Management, LLC ($35.5M), Birchview Capital, LP ($368K) and Brevan Howard Capital Management LP ($326K).
- Company
- Biohaven Pharmaceutical Hold
- CUSIP
- G11196105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $326K |
| Exits | 1 | $3K |
All 13F filers, Q2 2024 → Q3 2024: 6,523 shares bought and 88 shares sold, net +6,435 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Knoll Capital Management, LLC | 16.45% | No change | 710,422 | $35.5M |
| Birchview Capital, LP | 0.32% | No change | 7,365 | $368K |
| Brevan Howard Capital Management LP | 0.02% | New | 6,523 | $326K |
"% of holder's portfolio" is BIOHAVEN PHARMACEUTICAL HOLD's weight in each manager's 13F, not the share of Biohaven Pharmaceutical Hold the manager owns.